Complement activation and long-term graft function in ABO-incompatible kidney transplantation

doi:10.5527/wjn.v8.i6.95

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4551)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

312

WORD

181

HTML

2009

Figures (1-5)

167

Tables (1-4)

194

Sum=2863

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

658

Download

1030

Sum=1688

Oct 27, 2019 (publication date) through May 5, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Nephrol. Oct 27, 2019; 8(6): 95-108
Published online Oct 27, 2019. doi: 10.5527/wjn.v8.i6.95

Table 3 Infectious complications

		ABO-incompatible (n = 27)	ABO-compatible (n = 108)	P value
Total no. of infectious complications per patient		1.7 (1-2.3)	1.0 (0-2)	0.004
	CMV infections, (%)	12	11
	EBV infections, (%)	0	3
	BK infections, (%)	15	6
	Other viral infections, (%)	31	9
	First urinary tract infection, (%)	38	30
	Recurrent urinary tract infections, (%)	8	11
	Other bacterial infections, (%)	23	7
	Other infections, not otherwise specified, (%)	31	20

All values as percentages or median and interquartile range. P values calculated Mann Whitney U test or chi-square test where applicable. CMV: Cytomegalovirus; EBV: Epstein Barr virus.

Citation: van Sandwijk MS, Klooster A, ten Berge IJ, Diepstra A, Florquin S, Hoelbeek JJ, Bemelman FJ, Sanders JS. Complement activation and long-term graft function in ABO-incompatible kidney transplantation. World J Nephrol 2019; 8(6): 95-108
URL: https://www.wjgnet.com/2220-6124/full/v8/i6/95.htm
DOI: https://dx.doi.org/10.5527/wjn.v8.i6.95